SynthesisBMC infectious diseases2025
Management of malaria in newborns: a systematic review.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria in neonates (age ≤ 28 days) remains under-recognized and poorly characterized, without specific management guidelines. We conducted a systematic review to collate available evidence on antimalarial treatment in this age group.
methodsWe searched PubMed and Web of Science for studies reporting confirmed Plasmodium spp. infection and antimalarial treatment in neonates. Any type of study with original data, including case reports, was included if published in English, German or French. Demographic, clinical and antimalarial treatment data were extracted and summarized descriptively.
resultsOut of 4028 reports identified, 26 publications (22 case reports, three case series, one cross-sectional study) reporting on antimalarial treatment in 40 neonates with confirmed malaria were included. The majority (75%) of publications originated from malaria-endemic regions with 19 cases reported from African countries. Median age at symptom onset and diagnosis was 16 and 19 days, respectively. Plasmodium falciparum and P. vivax accounted for 45% and 43% of cases, one case had a P. falciparum and P. vivax co-infection, and in four cases species of Plasmodium was not reported. All but one neonate were reported with symptomatic malaria, with fever, jaundice, and anaemia as predominating symptoms; 70% were initially misdiagnosed with sepsis. Treatment regimens varied substantially. Of neonates with P. falciparum malaria, only 28% received artemisinin-based therapy and most (56%) were treated with oral amodiaquine or chloroquine monotherapy. P. vivax malaria was mostly treated with oral chloroquine (64%). Oral drug administration practice was rarely reported but included drug administration as syrup or crushed tablets and use of an orogastric tube. All patients survived, with reported parasitaemia clearance in 2–7 days.
conclusionThe literature on newborn malaria management remains notably sparse. Reported management practices are highly inconsistent with regimens deviating from current treatment recommendations. Prospective interventional studies on the management of malaria in newborns, including evaluation of oral drug administration practices and pharmacokinetics are urgently needed to inform evidence-based age-specific guidelines. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.